Patents Examined by Jon E. Angell
  • Patent number: 10072265
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: September 11, 2018
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Patent number: 9919058
    Abstract: Methods are disclosed herein for treating a subject with a lung cancer. The lung cancer can be small cell carcinoma of the lung or non-small cell carcinoma of the lung. The methods include locally administering to the subject a therapeutically effective amount of the polyketal particle comprising a CpG oligodexoynucleotide. Optionally, the polyketal particle can include an imidazoquinoline compound.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: March 20, 2018
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dennis M. Klinman, Takashi Sato
  • Patent number: 9885042
    Abstract: The present invention provides oligonucleotide inhibitors of miR-92 and methods of using said inhibitors for inhibiting the function and/or activity of miR-92 in a subject in need thereof. The present invention also provides methods for evaluating or monitoring the efficacy of a therapeutic for promoting wound healing and selecting a subject for treatment with a therapeutic that modulates miR-92 function and/or activity.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: February 6, 2018
    Assignee: MIRAGEN THERAPEUTICS, INC.
    Inventors: Christina Marie Dalby, Corrie Lynn Gallant-Behm, Aimee Jackson, Kathryn Hutnick, Anita Seto
  • Patent number: 9856475
    Abstract: This invention provides pharmaceutical compositions containing a UNA oligomer targeted to TTR and a pharmaceutically acceptable carrier. The compositions can be used in methods for treating or preventing TTR-related amyloidosis in a primate. The compositions, upon administering a single dose to the primate, can reduce TTR protein in the primate for a period of days to weeks.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: January 2, 2018
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Kiyoshi Tachikawa, Joseph E. Payne, Padmanabh Chivukula
  • Patent number: 9844562
    Abstract: The present invention concerns nanoparticles functionalized with duplex RNA for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a new strategy for conjugating RNA to a nanoparticle to achieve increased stability and activity.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: December 19, 2017
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, David A. Giljohann, Dwight S. Seferos, Andrew E. Prigodich, Pinal C. Patel
  • Patent number: 9809820
    Abstract: The present invention relates to a composition for reducing sweating in humans, characterized in that said composition comprises a compound capable of reduction of ITPR2 protein function and reduction of levels of ITPR2 mRNA and/or ITPR2 protein, and optionally pharmaceutically acceptable carriers and/or excipients, as well as to methods of treatment and specific siRNA molecules and their use in therapy.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: November 7, 2017
    Assignee: Hidros Therapeutics International AB
    Inventor: Niklas Dahl
  • Patent number: 9803197
    Abstract: This disclosure relates to particles conjugated to therapeutic nucleic acids. In certain embodiments, the nucleic acid comprises a sequence that catalytically cleaves RNA, e.g., DNAzyme or RNAzyme. In certain embodiments, the particles contain nucleic acids with both DNAzyme and/or RNAzyme and siRNA sequences. The cleaving nucleic acids optionally comprise a sequence functioning to hybridize to a target of interest and/or the particles are further conjugated to a targeting moiety. In certain embodiments, conjugated particles are used in the treatment or prevention of cancer or viral infections or bacterial infections. In certain embodiments, conjugated particles are used in detecting metal ions and other small molecule analytes.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: October 31, 2017
    Assignee: Emory University
    Inventors: Kevin Yehl, Salaita Khalid
  • Patent number: 9803195
    Abstract: Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: October 31, 2017
    Assignee: The Scripps Research Institute
    Inventor: Claes Wahlestedt
  • Patent number: 9803205
    Abstract: RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: October 31, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Steven B. Kanner, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
  • Patent number: 9796979
    Abstract: Disclosed herein are double stranded nucleic acid molecules and pharmaceutical compositions comprising same useful in the treatment of, inter alia, acute and chronic inflammation, neuropathic pain, primary graft dysfunction (PGD) after lung transplantation in a subject in need thereof. The compounds are preferably chemically synthesized and modified dsRNA compounds, which down regulate or inhibit expression of Toll like receptor 4.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: October 24, 2017
    Inventors: Elena Feinstein, Svetlana Adamsky, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
  • Patent number: 9790491
    Abstract: A novel compound to induce a pluripotent stem cell is provided. A novel anti-malignant-tumor substance is provided. A pluripotent stem cell-inducing agent, including a single-stranded or double-stranded polynucleotide containing the base sequence shown in SEQ ID NO:41 or a base sequence including deletion, substitution, or addition of 1 to 3 bases in SEQ ID No: 41, in which the pluripotent stem cell-inducing agent induces a cell to become a pluripotent stem cell is provided.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: October 17, 2017
    Assignee: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY
    Inventor: Norimasa Miura
  • Patent number: 9783808
    Abstract: The present invention provides ovarian cancer-specific aptamers, which are selected in vitro using SELEX and a microfluidic chip system. The aptamers can also bind to different histologically-classified ovarian cancer cells with high affinity accordingly. Therefore, the aptamers of the present invention and the applications thereof can not only be used in detection of ovarian cancer cells but also be applied in recognition of different histologically-classified ovarian cancer cells.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: October 10, 2017
    Assignee: National Tsing Hua University
    Inventors: Gwo-Bin Lee, Lien-Yu Hung, Chih-Hung Wang
  • Patent number: 9752146
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: September 5, 2017
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Patent number: 9730954
    Abstract: Disclosed are methods and compositions for using microRNA (miRNA) for treating cancer. The methods and compositions include hsa-miR-204 and homologs of hsa-miR-204.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: August 15, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Manjeet K. Rao, Jaafer S. Imam, Behyar Zoghi, Yao-Fu Chang, Panneerdoss Subbarayalu
  • Patent number: 9719088
    Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 1, 2017
    Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Eric N. Olson, Eva van Rooij
  • Patent number: 9719086
    Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 1, 2017
    Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Eric N. Olson, Eva van Rooij
  • Patent number: 9708609
    Abstract: The deficiency of Usf1 confers a remarkable number of clinically relevant beneficial metabolic effects in mice via activation of brown adipose tissue. The Usf1 deficient mice have high serum HDL-cholesterol and low triglyceride levels, a beneficial lipid profile opposite to that of human metabolic syndrome. The elevated HDL-C is associated with enhanced cholesterol efflux, and low triglycerides with decreased hepatic VLDL production and elevated triglyceride clearance. Despite their elevated food intake and lower physical activity, the Usf1 deficient mice are protected against diet-induced obesity. Their concomitant increase in energy expenditure is related to the activation of brown adipose tissue. The protective effects of Usf1 deficiency against obesity, insulin resistance, fatty liver, dyslipidemia, vascular inflammation, and atherosclerosis coupled with brown adipose tissue activation are demonstrated. Inhibition or silencing of USF1 is suggested as a therapeutic target to treat various human diseases.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: July 18, 2017
    Assignee: Terveyden ja hyvinvoinnin laitos (THL)
    Inventors: Pirkka-Pekka Laurila, Jarkko Soronen, Matti Jauhiainen, Anu Jalanko
  • Patent number: 9701956
    Abstract: A method for the in vitro production of DNA minicircles includes steps of: a) providing nicked double-stranded oligodeoxynucleotides bunt-ended substrates having at least one phosphorylated 5? end, b) performing a ligase-mediated circularization on a reaction mixture including the nicked double-stranded oligodeoxynucleotides substrates and a DNA bending protein, and c) obtaining DNA minicircles.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 11, 2017
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Marc Malinge, Patrick Midoux, Thomas Thibault, Chantal Pichon
  • Patent number: 9701961
    Abstract: The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: July 11, 2017
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Elena Feinstein, Evgenia Alpert, Igor Mett, Amir Bar-Ilan, Igor Spivak, Hagar Kalinski, Natanja Slager
  • Patent number: 9702880
    Abstract: Provided is the use of antisense RNA and methods for the treatment, diagnosis and prophylaxis of cancer comprising administering said antisense RNA, particularly miRs 15 and 16 to a patient in need thereof.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: July 11, 2017
    Assignee: Instituto Superiore Di Sanita
    Inventors: Desiree Bonci, Ruggero De Maria